Shane Schaffer

Shane Schaffer is the Co-founder, Chairman, and Chief Executive Officer of Cingulate Therapeutics, a Phase 3 clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas. Specializing in several branded next-generation pharmaceutical products, the company primarily targets Attention Deficit/Hyperactivity Disorders (ADHD), along with other therapeutic areas such as anxiety disorders and insomnia.

Industry Expertise

With a 25-year career in the pharmaceutical industry, he has specialized in drug development and commercialization. His strategic leadership and entrepreneurial approach have significantly impacted various business operations, including product launches, brand planning, joint venture brand management, life cycle management, and market development, establishing him as a notable figure in biopharmaceutical and marketing.

Educational Background

He earned his doctoral degree in Pharmacy from the University of Kansas in 1999. Later, he enhanced his expertise with a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. During his fellowship, he engaged in significant projects at Pfizer Worldwide Marketing and Morris Plains, sharpening his pharmaceutical marketing and management skills.

Pfizer Worldwide Marketing, New York, NY

At Pfizer, he served as a Marketing Manager, where he developed pre-launch strategies and initiated the Global Communications Intranet, facilitating improved communication between medical and marketing stakeholders. He also played a pivotal role in the creation and execution of the Pfizer Medical and Academic Partnership in Pain Management.

Morris Plains, New Jersey

At Morris Plains, he was appointed as project manager and external research manager. His responsibilities included leading advanced sales training and managing development programs. He also served as a Product Launch Trainer for femhrt®. He initiated Phase IV Medical Research for all marketed brands within the Parke-Davis Medical and Scientific Affairs division.

Professional Career

Throughout his career, Shane Schaffer held several managerial positions at Pfizer, Novartis, and Sanofi, where he developed and commercialized several billion-dollar brands.

Novartis Pharmaceuticals Corporation

Dedicated to the pharmaceutical industry, he joined Novartis as a Product Manager for the Ritalin® LA / Focalin™ segments in June 2001, significantly enhancing the company's ADHD franchise through strategic leadership and innovative executions.

Ritalin® LA & Focaline

He successfully launched Ritalin® LA and Focaline, achieving 166% and 114% budget attainment respectively. These medications, used for treating ADHD, reached 90% product awareness within three months of launch under his leadership, earning him the Novartis Business Excellence Award.

ADHD Franchise

In 2004, he headed all operations of the ADHD franchise, initiating a groundbreaking faculty development program that trained over 1,400 speakers in three months. His outstanding contributions to market and consumer engagement earned him multiple Novartis awards, including the PREMIER Award and the Novartis Ovation "Above and Beyond" Awards from 2001 to 2003.

Sanofi-Aventis

After Novartis, he continued to drive results at Sanofi Aventis during its crucial merger and joint venture phases, applying his dynamic professional expertise to impact the company's strategy and market presence significantly.

Entrepreneurial Ventures

After his tenure at Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant, leading the development of pre-med business opportunities and managing a team responsible for primary pharmaceutical targets. In July 2009, he founded Sabre Scientific Solutions, LLC, providing strategic consulting services across commercials, clinical, LCM, product launch, and leadership domains.

Cingulate Therapeutics LLC

His passion for addressing ADHD and anxiety disorders led to the establishment of Cingulate Therapeutics LLC in January 2013. Under his leadership, the company has focused on innovating drug delivery technologies to improve treatment efficacy and reduce patient dependency on traditional medications.

Partnership with Indegene

Cingulate has partnered with Indegene to market its phase-3 oral ADHD medication, CTx-1301. This collaboration aims to enhance the development and marketing efforts, positioning the medication for successful commercialization.

Future Outlook

Cingulate is poised to submit a new drug application for CTX-1301 by mid-2025, a significant step toward FDA approval and market introduction.

Philanthropic Commitment

Beyond his professional role, Shane Schaffer is actively involved with the Folds of Honor Charity, which provides educational scholarships to children affected by the loss or disability of military personnel. This reflects his commitment to social responsibility.